May 13
Respirion offers hope for people living with cystic fibrosis
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectSince 1998, the Harry Perkins Institute of Medical Research has grown to become one of the nation’s leading adult medical research centres, where a close-knit team of more than 400 research and trial staff work together to defeat the major diseases that impact our community. Our teams investigate a wide range of diseases, with a strong focus on cancer, cardiovascular disease, diabetes and neurogenetic diseases. Our world-class scientists, doctors and researchers are inspired to pursue vital research initiatives to build a healthier future for everyone.
The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) is an integrated multi-disciplinary research institute bringing together the skills of world-class researchers in the areas of bioengineering and nanotechnology.
ViewMater Research is a recognised leader in medical research. Our bench to bedside philosophy sees us working across Mater Health’s hospitals and health services, The University of Queensland, and the world-class Translational Research Institute (TRI).
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreFunding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Read moreENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
Read morePathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Read more